Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, initiated U.S. sites for its RE-VERSE AD trial, a phase III study testing the abilities of its humanized antibody fragment idarucizumab to act as an antidote to its anticoagulant Pradaxa (dabigatran etexilate mesylate) when patients require emergency intervention or experience an uncontrolled or life-threatening bleeding event.